Patent ID: 7875427

Claim:
A method for monitoring a response to IL-13 therapy in a patient undergoing IL13 therapy by measuring IL-13 associated-biomarker total RNA expression, comprising: (a) in a first PBMC sample taken from a patient to be administered with IL-13 therapy, measuring the total RNA expression of a biomarker selected from the group consisting of WNT5A and MPIF-1(CCL23); (b) administering IL-13 therapy to said patient; (c) in a second PBMC sample taken from said patient after administering said IL-13 therapy, measuring the total RNA expression of a biomarker selected from the group consisting of WNT5A and MPIF-1 (CCL23); and (d) comparing between the first and second PBMC samples, the level of biomarker total RNA expression, wherein said biomarker is selected from the group consisting of WNT5A and MPIF-1 (CCL23) wherein a reduction in biomarker expression is indicative of a reduction in IL-13 activity following administering said IL-13 therapy.